Progressive multiple sclerosis treatment considerations in the UK: Experience from trials and real-world population
| Autor: | Sean Apap Mangion, Jeremy Chataway |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Advances in Clinical Neuroscience & Rehabilitation, Vol , Iss (2024) |
| Druh dokumentu: | article |
| ISSN: | 1473-9348 2397-267X |
| DOI: | 10.47795/IRIH6781 |
| Popis: | The recent availability of disease modifying treatments (DMTs) for progressive multiple sclerosis (PMS) is a welcome change, yet the limitations of clinical trial design and the real-world makeup of the PMS population necessitate a balanced view of their potential benefits and risks in a population that is on average older than the relapsing-remitting MS (RRMS) population, and more likely to have or develop comorbidities over time. Here we will review the available data for DMT efficacy and risks in PMS with a view to guiding clinician and patient in joint care decision making. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|